Camille Bedard

Oct 7, 2024 | nature.com | Camille Bedard |Isabelle Gagnon-Arsenault |Alexandre K. Dubé |Alicia Pageau |Anna Fijarczyk |Rebecca Shapiro

AbstractAzole antifungals are the main drugs used to treat fungal infections. Amino acid substitutions in the drug target Erg11 (Cyp51) are a common resistance mechanism in pathogenic yeasts. How many and which mutations confer resistance is, however, largely unknown. Here we measure the impact of nearly 4,000 amino acid variants of Candida albicans Erg11 on the susceptibility to six clinical azoles. This was achieved by deep mutational scanning of CaErg11 expressed in Saccharomyces cerevisiae.